Weight Loss Jabs: NHS Faces £20 Billion Crisis
Exclusive investigation reveals the soaring financial and human cost of new obesity drugs. As millions rely on Wegovy and Ozempic, the NHS faces a multi-billion pound dilemma when patients stop treatment and weight returns.